Skip to content
Option Beast

Option Beast

  • Home
  • Business
  • Top News
  • Economy
  • Domestic
  • Money
  • Newsletters
Top News
Signed June 22. Announced Nowhere.
Consumer Confidence at 81.9: Fuel Shock or Spending Recession?
Tesla Reports Friday. Bet the Size of the Move.
ZIM Trades at $30 With a $35 Buyout on the Table. That Gap Is the Opportunity.
Elon Musk’s AI Agent Could 70X Investors’ Money
Signed June 22. Announced Nowhere.
Newsletters

Signed June 22. Announced Nowhere.

September 30, 2026 Bonus Content: Berlin Is Stalling the UniCredit-Commerzbank Deal. Options Look Risky. A note from our friends at…

September 30, 2026
Consumer Confidence at 81.9: Fuel Shock or Spending Recession?
Economy

Consumer Confidence at 81.9: Fuel Shock or Spending Recession?

Portfolio managers are splitting retail into two camps. Tuesday’s data forced that choice.

September 30, 2026
Tesla Reports Friday. Bet the Size of the Move.
Newsletters

Tesla Reports Friday. Bet the Size of the Move.

Sixty thousand vehicles. That is the gap separating the most optimistic Wall Street delivery forecast for Tesla from the most…

September 30, 2026
ZIM Trades at $30 With a $35 Buyout on the Table. That Gap Is the Opportunity.
Business

ZIM Trades at $30 With a $35 Buyout on the Table. That Gap Is the Opportunity.

Hapag-Lloyd just raised its 2026 outlook again, yet ZIM’s union rejection keeps the spread stubbornly wide.

September 29, 2026
Elon Musk’s AI Agent Could 70X Investors’ Money
Newsletters

Elon Musk’s AI Agent Could 70X Investors’ Money

A note from our friends at Brownstone Research(ad) Editor’s Note: Former tech executive Jeff Brown picked Nvidia in 2016. It’s…

September 29, 2026
Evonik Rejected BASF’s Bid. RAG-Stiftung May Decide What’s Next.
Politics

Evonik Rejected BASF’s Bid. RAG-Stiftung May Decide What’s Next.

Evonik closed at €19.84 and BASF’s reported €22.15 offer was rejected. The key question is whether RAG-Stiftung will support any deal terms.

September 29, 2026
Pharma Is Turning IV Drips Into Injections to Dodge the Patent Cliff
Newsletters

Pharma Is Turning IV Drips Into Injections to Dodge the Patent Cliff

There is a $300 billion problem sitting inside the world’s largest drug companies, and the industry’s answer to it is…

September 29, 2026
Chinese AI Models Took 57% of Developer Tokens. Who Keeps the Margin?
Economy

Chinese AI Models Took 57% of Developer Tokens. Who Keeps the Margin?

When price beats performance on the platforms where developers route real work, ask which layer of the AI stack still earns a defensible return.

September 28, 2026
They May Rename Silicon Valley After This
Newsletters

They May Rename Silicon Valley After This

September 28, 2026 Bonus Content: Mirum’s Phase 3 Hepatitis Delta Data Drops Before the Bell A note from our friends…

September 28, 2026
This Nor’easter Hits Travelers’ Bottom Line in Three Weeks
Business

This Nor’easter Hits Travelers’ Bottom Line in Three Weeks

A rare September nor’easter is still battering the Jersey Shore. The damage will land directly in Travelers’ Q3 results on October 16.

September 28, 2026

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Sign up for our free Option Beast Newsletter!

Discover new market trends and ideas directly to your inbox.

By providing your email, you agreed to receive informational and promotional messages from us. You may opt out at any time by clicking the unsubscribe at the bottom of each email. See our Privacy Policy for more information.

Recent Posts

  • Signed June 22. Announced Nowhere.
  • Consumer Confidence at 81.9: Fuel Shock or Spending Recession?
  • Tesla Reports Friday. Bet the Size of the Move.
  • ZIM Trades at $30 With a $35 Buyout on the Table. That Gap Is the Opportunity.
  • Elon Musk’s AI Agent Could 70X Investors’ Money
  • Evonik Rejected BASF’s Bid. RAG-Stiftung May Decide What’s Next.
  • Pharma Is Turning IV Drips Into Injections to Dodge the Patent Cliff

Categories

  • Business
  • Economy
  • Newsletters
  • Politics
  • Top News
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms of Service/Use Agreement
  • Contact Us

Copyright 2026 © All rights reserved | Option Beast | optionbeast.com

SITE_OK
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}